LEOCLAN Co. Ltd. AI Stock Analysis
Want to see JP:7681 full AI Analyst Report?
LEOCLAN Co. Ltd. (7681) AI Stock Analysis
LEOCLAN Co. Ltd.
(TSE/TYO:7681)
The overall score of 60 reflects a company in the midst of a high-stakes transformation. The primary strength is the successful initial integration of a major acquisition, which has led to a massive increase in revenue and a swing to robust positive free cash flow. This is offset by the primary risk: a highly leveraged balance sheet that leaves little room for error. The weak technical trend further pressures the score, while the reasonable valuation and dividend yield provide some downside support. The company's future hinges on its ability to sustain strong cash flows to deleverage and improve razor-thin profit margins.
LEOCLAN Co. Ltd. (7681) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.12B
- Dividend Yield
- 1.97%
- Average Volume (3M)
- 1,476
- Price to Earnings (P/E)
- 14.7
- Beta (1Y)
- -0.01
- Revenue Growth
- 118.29%
- EPS Growth
- 125.76%
- Country
- Japan
- Employees
- 155
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
LEOCLAN Co. Ltd. Business Overview & Revenue Model
Company Description
LEOCLAN Co.,Ltd. operates as a medical equipment trading firm, addressing diverse needs across medical care, welfare, and general health sectors. Its operations are structured into three main divisions: Medical Total Solutions Business, Remote Image...
LEOCLAN Co. Ltd. Financial Statement Overview
Summary
Financial performance is a tale of transformation. Revenue and operating cash flow have surged due to a major acquisition, and EBIT has nearly tripled, indicating effective scaling. However, net margins remain extremely thin (below 1%), and the balance sheet is now highly leveraged with a debt-to-equity ratio of 0.79, introducing significant financial risk. The overall picture is of a much larger, cash-generative company that must now prove it can manage its debt and improve profitability.
Income Statement
72PositiveBalance Sheet
45NeutralCash Flow
78Positive| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.47B | 46.91B | 21.49B | 19.80B | 26.63B | 29.77B |
| Gross Profit | 4.99B | 6.15B | 2.74B | 2.62B | 2.82B | 3.06B |
| EBITDA | 916.42M | 1.24B | 400.58M | 375.47M | 553.93M | 789.05M |
| Net Income | 115.68M | 346.69M | 152.78M | 136.06M | 271.31M | 437.05M |
Balance Sheet | ||||||
| Total Assets | 22.30B | 22.73B | 10.91B | 10.66B | 14.75B | 13.52B |
| Cash, Cash Equivalents and Short-Term Investments | 8.78B | 6.45B | 4.78B | 5.57B | 5.54B | 5.48B |
| Total Debt | 4.90B | 4.66B | 7.19M | 12.57M | 5.67M | 99.82M |
| Total Liabilities | 16.28B | 16.65B | 5.09B | 4.93B | 9.02B | 7.98B |
| Stockholders Equity | 5.83B | 5.88B | 5.63B | 5.57B | 5.57B | 5.38B |
Cash Flow | ||||||
| Free Cash Flow | -116.70M | 1.03B | -116.70M | 17.72M | 291.06M | 215.57M |
| Operating Cash Flow | -86.65M | 1.66B | -86.65M | 33.08M | 341.56M | 242.36M |
| Investing Cash Flow | -619.82M | -4.33B | -619.82M | 100.75M | -82.01M | -49.96M |
| Financing Cash Flow | -100.73M | 4.35B | -100.73M | -97.22M | -202.31M | -120.93M |
LEOCLAN Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7681, the sentiment is Negative. The current price of 864.00 is below the 20-day moving average (MA) of 888.90, below the 50-day MA of 942.84, and below the 200-day MA of 909.93, indicating a bearish trend. The MACD of -28.76 indicates Negative momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7681.
LEOCLAN Co. Ltd. Peers Comparison
Overall Rating
JP:768160Neutral
JP:497845Neutral
JP:777442Neutral
JP:375040Underperform
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | JPY 5.12B | 14.74 | ― | 1.97% | 118.29% | 125.76% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | JPY 11.75B | -24.37 | ― | ― | -8.23% | -48.10% | |
| 42Neutral | JPY 26.03B | -70.96 | ― | ― | 17.05% | 10.47% | |
| 40Underperform | JPY 6.70B | -13.85 | ― | ― | 101.85% | 73.33% | |
| 38Underperform | JPY 7.77B | -4.21 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 6.07B | -4.74 | ― | ― | -49.43% | -3.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7681 | LEOCLAN Co. Ltd. | 864.00 | -44.28 | -4.87% | |
| JP:3750 | Cytori Cell Research Institute, Inc. | 750.00 | -62.00 | -7.64% | |
| JP:4599 | StemRIM Inc. | 124.00 | -154.00 | -55.40% | |
| JP:4978 | ReproCELL Inc. | 110.00 | -51.00 | -31.68% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 641.00 | 156.00 | 32.16% | |
| JP:7776 | CellSeed Inc. | 153.00 | -146.00 | -48.83% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
